Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
19,139,684
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
6,818,719
-
Shares change
-
+6,818,366
-
Total reported value, excl. options
-
$60,295,418
-
Value change
-
+$60,292,297
-
Put/Call ratio
-
71%
-
Number of buys
-
61
-
Price
-
$8.84
Significant Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) as of Q2 2025
64 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 as of Q2 2025.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6,818,719 shares
of 19,139,684 outstanding shares and own 36% of the company stock.
Largest 10 shareholders include ARCH Venture Management, LLC (1,820,634 shares), Foresite Capital Management IV, LLC (800,399 shares), Almitas Capital LLC (579,997 shares), venBio Partners LLC (473,479 shares), VANGUARD GROUP INC (442,626 shares), Foresite Capital Management V, LLC (406,652 shares), PRICE T ROWE ASSOCIATES INC /MD/ (306,059 shares), Alphabet Inc. (293,256 shares), CITADEL ADVISORS LLC (271,283 shares), and HSG Holding Ltd (152,299 shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.